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Fixed-dose combination therapy for Parkinson’s disease with a spotlight on 
entacapone in the past 20 years: a reduced pill burden and a simplified dosing 
regime
András Salamona, Dénes Zádoria, László Szpisjaka, Péter Klivényia and László Vécseia,b
aDepartment of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary; bDepartment of 
Neurology and Interdisciplinary Excellence Centre, Faculty of Medicine, MTA-SZTE Neuroscience Research Group, Szeged, Hungary
ABSTRACT
Introduction: Parkinson’s disease (PD) is a progressive, chronic neurodegenerative disorder. The main 
neuropathological cause of the disease is the death of dopaminergic neurons in the substantia nigra. 
Unfortunately, there is no curative treatment yet. The gold-standard of the treatment is levodopa (LD). 
During the course of the disease, motor complications develop, which postulates the addition of 
entacapone (ENT) to the dopaminergic medication. Previous studies have suggested that patients 
have a better quality of life when entacapone is added in a combination with LD.
Areas covered: A systematic literature search was performed. Articles were identified through PubMed 
(MEDLINE), Web of Science, Ovid, and ClinicalTrials.gov databases. The following search terms were 
used: ‘Levodopa’ AND ‘Carbidopa’ OR ‘Benserazide’ AND ‘Entacapone’. The search period was between 
2000 and 2020. Twenty randomized and 10 non-randomized clinical trials (12,893 subjects) were 
included in the qualitative analysis. The systematic review was written in line with the PRISMA 
guideline.
Expert opinion: ENT administered in combination with LD resulted in a better quality of life compared 
to separate tablets. Therefore, in PD patients where impaired motor performance develops and the 
application of entacapone is necessary, it is suggested to be administered in a single tablet form.
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Parkinson’s disease is the second most common neurodegen-
erative disorder [1]. The estimated prevalence is around 
10–18 per 100 000 [2]. The most important motor symptoms 
are bradykinesia, tremor, and/or rigidity [2]. The main neuro-
pathological cause of the disease is the death of the dopami-
nergic neurons in the substantia nigra [3]. Unfortunately, there 
is no curative treatment yet, however extensive preclinical and 
clinical studies are ongoing [4]. Today, the focus of treatment 
is on the compensation of the hypodopaminergic state of the 
brain with exogenous levodopa (LD) substitution [5]. In gen-
eral, a significant proportion of levodopa is rapidly metabo-
lized by the peripheral aromatic amino-acid decarboxylase 
(AADC) [6–8]. To prevent this process, dopa-decarboxylase 
inhibitors (DDCI) have been introduced in daily clinical prac-
tice (benserazide (B) and carbidopa (CD)) [6–8]. However, 
AADC is not the only enzyme which is involved in this meta-
bolic pathway [6–8]. Catechol-O-methyltransferase (COMT) can 
also convert LD to 3-O-methyldopa (3-OMD) [6–8]. To block 
this pathway as well, three widely known COMT inhibitors 
(entacapone (ENT), tolcapone (TLC), and opicapone (OPC)) 
have been introduced [6–8]. Although ENT is the most widely 
used COMT inhibitor, it requires multiple daily doses. In con-
trast, it is sufficient to administer OPC once a day. The only 
central acting COMT inhibitor is TLC; however, due to its 
hepatotoxic effects, it should be closely monitored [6]. The 
treatment of patients with Parkinson’s disease becomes very 
complicated as the disease progresses [5]. The ‘ON’-time will 
get shorter and the number of hours with inappropriate 
movement increases [5]. Fractionation and intensification of 
the LD treatment gradually become necessary [5]. If end-of- 
dose motor fluctuations develop, an option is to introduce the 
COMT-inhibitors in combination with LD/DDCI [5]. In addition 
to the motor symptoms of the disease, many non-motor 
symptoms, including Parkinson’s dementia are known [9]. 
Given that the treatment strategy gets more complicated as 
the disease progresses and, simultaneously, the condition of 
the patient gradually deteriorates, combination therapies play 
a major role in achieving optimal compliance and therapeutic 
response [5]. Furthermore, the cost-effectiveness of combina-
tion therapies is not negligible [10].
For the reasons mentioned above, the primary aim of this 
systematic review is to summarize the efficacy data on enta-
capone as an adjunct therapy to LD on motor fluctuations (in 
line with PRISMA criteria [11]). Furthermore, the secondary 
objective is to compare the pharmacological and quality of 
life effects of two modes of oral ENT administration (LD/DDCI 
plus ENT separately versus LD/DDCI/ENT). An additional pur-
pose of our study is to demonstrate the importance of 
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English language, available online reviews, editorial articles, and 
original publications have been included in the systematic lit-
erature analysis, as well as clinical trials with accessible results. 
The search period was between 2000 and 2020 (January). 
Clinical trials on individuals below the age of 18 are not included 
in the analysis. The main focus of the literature search was on 
the effect of ENT on the motor performance of Parkinsonian 
patients. Due to the lack of LD combination formulation for OPC 
and TLC, it was not possible to compare these with ENT combi-
nations. For this reason, OPC and TLC were beyond the scope of 
this article. Furthermore, the studies addressing the impact of 
ENT on levodopa-induced hyperhomocysteinemia and vitamin 
B12 deficiency were also excluded.
2.2. Information sources and search strategy
Articles were identified through PubMed (MEDLINE), Web of 
Science, Ovid, and ClinicalTrials.gov databases. The following 
search terms were used in all applied online databases: 
‘Levodopa’ AND ‘Carbidopa’ OR ‘Benserazide’ AND ‘Entacapone’.
2.3. Data items
The following information was searched in the identified pub-
lications: (1) type of the trial; (2) participant characteristics 
(number of included subjects, inclusion, and exclusion criteria); 
(3) purpose of the study; (4) intervention and groups; (5) 
duration of the study; (6) clinical assessment scales; (7) out-
come measures (primary and secondary); (8) main findings.
3. Results
3.1. Study selection process
Through PubMed (MEDLINE) searches 179 items were identi-
fied (Figure 1). Using the Web of Science, Ovid, and 
ClinicalTrials.gov databases, we identified an additional 497 
items. Duplications were removed using Mendeley software 
(n = 208). After screening the 468 identified findings (titles and 
abstracts were read), 39 articles were eligible for full-text 
review. After the detailed evaluation of the above-mentioned 
texts, 30 studies were included in this systematic analysis.
3.2. Study characteristics
Study type – 20 randomized (double-blind, cross-over (n = 8); 
double-blind, parallel-group (n = 5); single-blind, cross-over 
(n = 1); single-blind, parallel-group (n = 1); open-label, cross- 
over (n = 2); open-label, parallel-group (n = 3)) and 10 non- 
randomized (open-label) clinical trials were identified (Table 1).
Number and characteristics of participants – 12,893 subjects 
(male and female patients) were involved in these studies (PD 
patients = 12,784; healthy subjects = 109). Age range: 30 to 
80 years.
Inclusion and exclusion criteria (PD population) – The most 
widely used inclusion criteria were the following: (1) – idiopathic 
PD; (2) – Hoehn-Yahr stage 1 to 3; (3) – motor fluctuation 
information (absent; no or minimal, nondisabling motor fluctua-
tion; ‘end-of-dose type’; wearing-off; on-off phenomenon; early 
end-of-dose wearing-off defined by QUICK questionnaire; mild 
wearing-off phenomena; without unpredictable fluctuations; 
wearing-off with or without mild dyskinesia; at least 1 ‘yes’ on 
the Motor Fluctuation Questionnaire) (4) – LD dose (stable dose; 
not optimally treated) and formulation information (standard; IR; 
SR; RR). The main exclusion criteria used in the studies were the 
following: (1) – secondary or atypical parkinsonism; (2) – severe 
systemic or psychiatric illness; (3) – previous or current treatment 
which interferes with the tested drug; (4) – previous treatment 
with ENT; (5) – motor performance information (unpredictable 
dyskinesia; unpredictable ”OFF” periods; painful dyskinesia; dis-
abling dyskinesia; unpredictable fluctuations; complex motor 
fluctuations; severe dyskinesia; more than mild dyskinesia).
Duration of the study – the duration of the studies ranged 
from 2 days to 136 weeks.
Clinical assessment scales – the following tests were generally 
used in the identified clinical trials: (1) – UPDRS scale; (2) – PDQ-39 
and −8; (3) – SF-36; (4) – PSI; (5) – VAS; (6) – Clinical Global 
Impression (patient and investigator); (7) – Motor fluctuations 
Questionnaire; (8) – QoL; (9) – ESS; (10) – MMSE; (11) – Schwab 
and England ADL scores; (12) – BDI; (13) – Wearing Off Card; (14) – 
Motor performance tests (grip strength, line tracing test, peg 




The majority of the performed pharmacokinetic studies 
focused on the effect of ENT on LD in different administration 
Article highlights
● Parkinson’s disease is the second most common neurodegenerative 
disorder with an estimated prevalence of around 10-18 persons per 
100 000.
● The gold-standard of the treatment is levodopa (LD). However, dur-
ing the course of the disease, motor complications develop which 
often leads the prescription of entacapone (ENT) in addition to the 
dopaminergic medication.
● ENT is a peripherally acting COMT-inhibitor.
● ENT administered in combination (LD/CD/ENT) results in a better 
quality of life compared to the drugs administered separately (LD/ 
CD + ENT or LD/B + ENT)
● The cost-effectiveness of combination formulations may be an impor-
tant future aspect for the patient’s and health insurance’s budget, 
especially as an increased QoL could increase a patient’s number of 
active years and reduce the need for hospital care.
This box summarizes key points contained in the article.
2 A. SALAMON ET AL.
and combination settings. There was no relevant pharmacoki-
netic difference between LD/CD and LD/B after ENT adminis-
tration. However, other authors [16] suggested, that LD/B may 
have more significant AADC inhibitory effects. Addition of ENT 
to LD/CD or LD/B resulted in increased AUC and decreased 
3-OMD levels (regardless of the type of the LD formulation 
(e.g. RR, CR, IR; separately administered or single tablet form)) 
[17–24].
3.3.2. Scale-based assessments, motor performance
To estimate the alteration in motor performance, UPDRS scale 
was the most widely used [26–37 and NCT00391898, 
NCT00642356]. The overall conclusion of many of the identi-
fied studies was that regardless of the administration form of 
ENT (administered separately or in single tablet form), motor 
performance improved [20,25–27]. This positive effect is also 
detectable in different subpopulations (e.g. in early-stage PD 
patients) [25]. However, in the STRIDE-PD clinical trial, an ear-
lier appearance and increased frequency of dyskinesias were 
detected in the ENT group [26]. Interestingly, in the SIMCOM 
study, a pronounced improvement was found in the UPDRS 
score (the mean UPDRS score (parts III) improved significantly 
(from 24.0 by 1.9; p < 0.01)) with the single tablet LD/CD/ENT 
group compared to LD/CD plus ENT (separately) group [28]. 
The repeated administration of ENT containing LD combina-
tion resulted in significantly better motor scores (UPDRS) and 
performance in comparison to repeated administration of LD/ 
CD alone, meanwhile, there was lesser pronounced fluctuation 
of movements [23]. In the START-M trial – similarly to the TC- 
INIT study – a switch from the previous LD medication to LD/ 
CD/ENT resulted in a 29% reduction rate on the UPDRS [29].
3.3.3. Quality of life
The effect of entacapone addition to LD/DDCI and the formu-
lation-related effects (LD/DDCI + ENT vs. LD/CD/ENT) were also 
examined from the perspective of QoL.
Hauser et al. found over 39 weeks, in early PD populations, 
that LD/CD/ENT resulted in greater clinical improvement than 
LD/CD alone [25]. The risk of motor complications was not 
elevated in the ENT group [25]. ADL (Part II, UPDRS, p = 0.025) 
and Schwab and England scores (by patient: p = 0.006, by 
rater: 0.003) were significantly better in the LD/CD/ENT group 
[25]. There was a similar tendency with the PDQ-39 and PDQ-8 
scores [25]. The p-CGI was significantly better as well in the 
above-mentioned group (LD/CD group – 34.8% reported that 
they were ‘much improved’; however, in the LD/CD/ENT group 
it was 36.7%) [25]. Another study found that in patients with-
out motor complications, separately administering ENT for 
21 weeks did not improve the ADL section of UPDRS scale 
[30]. However, this treatment resulted in a significant improve-
ment in the QoL measures (PDQ-39 (p = < 0.01), SF-36 (vitality 
domain – p = 0.04; physical component – p = 0.009), PSI 
Figure 1. PRISMA flow diagram.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT OPINION ON PHARMACOTHERAPY 9
(frequency – p = 0.007) and subject clinical global assessment 
(p = 0.02) [30]. The most affected domains of the PDQ-39 scale 
were mobility (p = 0.001) and ADL (< 0.001) [30]. The conver-
sion from SR LD/CD to LD/CD/ENT resulted in a significant 
improvement in QoL measures after 1 month [27]. The UPDRS 
(motor score, total score) and the ‘mobility’, ‘ADL’, ‘emotional’, 
‘cognition’ and ‘bodily discomfort’ domains of PDQ-39 scale 
improved significantly [27]. These patients also had better 
scores on the Epworth Sleepiness Scale (ESS) [27]. In the 
12 weeks study [31] (184 patients, no or minimal, nondisabling 
motor fluctuation), the effect of LD/DDCI compared to LD/CD/ 
ENT on the quality of life was investigated. The applied PDQ-8 
scale significantly improved in the LD/CD/ENT group 
(p = 0.021) [31]. The most affected parts of the PDQ-8 scale 
were ‘depression’ (p = 0.025), ‘close personal relationship’ 
(p = 0.037), ‘communication’ (p = 0.007) and ‘social stigma’ 
(p = 0.033) [31]. In another comparative study [32], over 70% 
of the patients in both groups (LD/CD + ENT and. LD/CD/ENT) 
felt that their clinical condition was better after the switch 
from the previously applied medication (LD/DDCI). Over 80% 
of patients experienced a reduction of fluctuations (87% – 
combination; 81% – separate ENT) [32]. In the SELECT-TC 
study [33], the effect of switching from IR LD/DDCI to LD/ 
CD/ENT on QoL was estimated in a 4 week study of patients 
with wearing-off. The total score of the PDQ-39 scale 
improved significantly (p = < 0.001). Most of the patients 
reported a slight improvement on the p-CGI scale (34.9%) 
[33]. Consistently with these results in a similar study [29], 
the activities of daily living improved by 25.1% as well. The 
effect of the switch from different DDCI inhibitors (LD/CD or 
LD/B) to LD/CD/ENT was tested as well [34]. It was found that 
after switching 77% of patients reported ‘improvement’ 
(p-CGI: LD/CD to LD/CD/ENT: p = 0.008; LD/B to LD/CD/ENT: 
p = < 0.0001). There was a significant improvement in the 
i-CGI-C, UPDRS and QoL-VAS scales as well [34]. Furthermore, 
it seems that an immediate switch (IS) from LD/CD to LD/CD/ 
ENT, compared to a delayed switch, has more advantages in 
terms of QoL [35]. At week 8, the PDQUALIF (p = 0.0133) and 
PDQ-39 (p = 0.0136) total scores were significantly lower in the 
IS group [35].
In the SIMCOM study [28], the effect of the switch from 
separately administered LD/CD + ENT to LD/CD/ENT (single 
tablet) was tested. 69% of the patients preferred (54%, N.S.) 
LD/CD/ENT or considered it equivalent (15%) to previously 
applied treatments (N.S.). Eighty-five percent of the patients 
in the LD/CD/ENT group found the clinical condition equal 
or better (evaluated by investigator, 75% if the patients 
evaluated themselves). The patients rated LD/CD/ENT easier 
to handle (84%), remember (67%) and swallow (59%) [28]. 
The treated group found it convenient to use LD/CD/ENT 
and found the dosage simpler (94%) [28]. In a previously 
mentioned comparative study (TC-INIT) [32] the QoL was 
significantly better as well in the LD/CD/ENT group (CGI-C 
scale: ‘very much improved’ – LD/CD + ENT (4%) versus LD/ 
CD/ENT (12%) compared to LD/CD + ENT group [32]. 
Furthermore, an important large retrospective study [36] 
was performed which tested the therapeutic adherence 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT OPINION ON PHARMACOTHERAPY 11
(LD/CD/ENT) forms. The use of LD/CD/ENT vs. LD/CD + ENT 
(separate tablets) resulted in better adherence (79% lower 
mean non-adherence; 86% lower odds of unsatisfactory 
adherence) [36]. As a conclusion, some studies suggest 
that the single tablet form results in a better QoL; however, 
no strong evidence is available so far.
4. Conclusions
The identified clinical trials provided data on the clinical and 
pharmacokinetic efficacy of ENT addition. Only a minority of 
the identified studies ([28,32,36]) compared the administration 
mode of ENT. The SIMCOM study proved that 69% of the 
patients preferred (54%, not significant) or considered equiva-
lent (15%) the LD combination in a single tablet [28]. 
Additionally, they felt their own clinical condition (85%) was 
significantly improved [28]. As opposed to separate dosing, 
patients found it easier to swallow (59%), handle (84%) or 
remember (67%) [28]. In the TC-INIT study, it was demon-
strated that the QoL measures were significantly better in 
the LD/CD/ENT group compared to the LD/CD + ENT group 
[32]. Furthermore, the only one involved cohort study (which 
included 8646 patients) found better patient adherence in the 
LD/CD/ENT combination group [36]. In conclusion, in PD 
patients where impaired motor performance justifies the addi-
tion of ENT to the previously applied treatment regimen, 
administration of the single tablet form is suggested.
5. Expert opinion
Although many factors (e.g. familial, financial, social) influence 
the adherence of a PD patient to the applied medication, the 
importance of non-motor symptoms should be emphasized. 
The prevalence of depression in Parkinson’s disease is 30–40% 
[37] and furthermore, around 30–40% of patients fulfill the 
diagnostic criteria of cognitive impairment (cumulative preva-
lence: up to 78%) [38]. These two non-motor symptoms have 
been demonstrated to have a relation with drug non- 
adherence in Parkinson’s disease, and therefore optimization 
and simplification (single pills) of dopaminergic therapy is very 
important to achieve the optimal therapeutic effects [39,40].
This systematic review summarizes the most important 
comparative studies regarding ENT administered separately 
and in combination. During these studies, the administered 
medicines were closely controlled (no medication error 
remained unexplained), the UPDRS score did not differ signifi-
cantly between the LD/CD/ENT versus LD/CD + ENT (sepa-
rately) groups [32]. Nonetheless, the majority of patients 
strongly preferred the combination products [28,32]. They 
felt it easier to handle, swallow, and to remember the appro-
priate dose [28]. The majority of the performed studies 
showed a reduction of daily levodopa dose, not only in PD 
patients who previously were not treated with ENT, but also 
after switching between separately administered ENT to 
a combination tablet [18,20–34,36,41–43].
From the pharmacokinetic perspective, there is a need for 
optimal timing of the oral administration of ENT to achieve 
the highest bioavailability of LD [16]. The possibility of incor-
rect administration (e.g. less frequent) of ENT is higher with 
separate tablets [36]. Furthermore, the widely applied pro-
ducts, which have distinct drug-releasing profiles (e.g. 
extended-, controlled-release), could make the pharmacoki-
netics more complex with an additionally increased preva-
lence of suboptimal LD brain concentration and 
inappropriate motor symptom control [44]. These facts sup-
port the hypothesis that ENT administered in combination 
yields better bioavailability. ENT addition has a risk of worsen-
ing dyskinesia intensity. Dyskinesia was one of the most 
important factors behind the dropouts (Table 2). The majority 
of studies showed a discrete reduction in the ‘OFF’ time; 
however, we think that ‘ON’ time is more relevant in judging 
the efficacy of the ENT treatment.
Examining the cost-effectiveness of combination formulations 
can be a very important future aspect for the patient’s and health 
insurance’s budget. A significantly better quality of life, as docu-
mented by clinical studies, is capable of increasing the number of 
active years and reducing the need for hospital care.
In summary, combination treatments (in particular, ENT 
combinations in the current work) have been shown to be 
more effective in terms of quality of life compared to sepa-
rately administered drugs. During the disease course, cogni-
tive and other non-motor problems, along with motor 
symptoms, become the leading reasons for non-adherence 
to medication and not appropriate movement control [36]. 
The final conclusion of this systematic literature review is 
that switching to combination ENT treatment in PD patients 
with end-of-dose wearing-off phenomena is a good option to 
achieve better QoL. However, patients with motor complica-
tions should be reevaluated from time to time regarding 
instrumental therapies for advanced disease stages [45].
Funding
This work was supported by the Hungarian Brain Research Program (No. 
2017-1.2.1-NKP-2017-00002_VI/4), the Hungarian National Research, 
Development and Innovation Office (NKFIH) through project GINOP 
2.3.2-15-2016-00034 and The Ministry of Human Capacities, Hungary 
through grant TUDFO/47138-1/2019-ITM.
Declaration of interest
The authors have no other relevant affiliations or financial involvement 
with any organization or entity with a financial interest in or financial 
conflict with the subject matter or materials discussed in the manuscript 
apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other 
relationships to disclose.
References
Papers of special note have been highlighted as either of interest (•) or of 
considerable interest (••) to readers.
1. Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed). 
2014;6:65–74.
2. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912.
12 A. SALAMON ET AL.
• An excellent summary of important aspects of Parkinson’s dis-
ease (symptoms, pathology, epidemiology, genetics, 
treatment)
3. Dickson DW. Neuropathology of Parkinson disease. Parkinsonism 
Relat Disord. 2018;46:S30–S33.
• Neuropathology of Parkinson’s disease. The author focuses on 
the most important neuropathological features of PD based 
upon personal experience as well. The article also includes cell 
biological and animal experimental data.
4. Salamon A, Zádori D, Szpisjak L, et al. Neuroprotection in 
Parkinson’s disease: facts and hopes. J Neural Transm (Vienna). 
2019. DOI:10.1007/s00702-019-02115-8.
5. Dietrichs E, Odin P. Algorithms for the treatment of motor pro-
blems in Parkinson’s disease. Acta Neurol Scand. 2017;136:378–385.
• Algorithm for the treatment of Parkinson’s disease. The authors 
propose an alternative for optimal treatment of Parkinsonian 
patients.
6. Marsala SZ, Gioulis M, Ceravolo R, et al. A systematic review of 
catechol-0-methyltransferase inhibitors: efficacy and safety in clin-
ical practice. Clin Neuropharmacol. 2012;35:185–190.
7. Annus Á, Vécsei L. Spotlight on opicapone as an adjunct to levo-
dopa in Parkinson’s disease: design, development and potential 
place in therapy. Drug Des Devel Ther. 2017;11:143–151.
8. Salamon A, Zádori D, Szpisjak L, et al. Opicapone for the treatment 
of Parkinson’s disease: an update. Expert Opin Pharmacother. 
2019;20:2201–2207.
9. Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms 
of Parkinson’s disease: diagnosis and management. Lancet Neurol. 
2006;5:235–245.
• An excellent summary paper detailing the non-motor symp-
toms of Parkinson’s disease.
10. Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of 
treatment of Parkinson’s disease with entacapone in the United 
States. Pharmacoeconomics. 2002;20:617–628.
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. 
BMJ. 2009;339:b2700.
•• A manuscript detailing the rules for writing a PRISMA review
12. Linazasoro G, Kulisevsky J, Hernández B, et al. Should levodopa 
dose be reduced when switched to stalevo? Eur J Neurol. 
2008;15:257–261.
•• From a clinical perpective, the aim of this important study was 
to determine the best way to switch from LD/CD to LD/CD/ENT. 
The reduction of the LD dose after switching did not result in 
the deterioration of motor performance.
13. LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokinetic- 
pharmacodynamic crossover comparison of two levodopa exten-
sion strategies. Mov Disord. 2009;24:1319–1324.
14. Kuoppamäki M, Leinonen M, Poewe W. Efficacy and safety of 
entacapone in levodopa/carbidopa versus levodopa/benserazide 
treated Parkinson’s disease patients with wearing-off. J Neural 
Transm (Vienna). 2015;122:1709–1714.
15. Park J, Kim Y, Youn J, et al. Levodopa dose maintenance or reduc-
tion in patients with Parkinson’s disease transitioning to levodopa/ 
carbidopa/entacapone. Neurol India. 2017;65:746–751.
•• A great study, which tries to determine the efficacy, safety and 
tolerability of the maintenance or reduction of the LD dose 
during a switch to an ENT containing combination.
16. Iwaki H, Nishikawa N, Nagai M, et al. Pharmacokinetics of levodopa/ 
benserazide versus levodopa/carbidopa in healthy subjects and 
patients with Parkinson’s disease. Neurol Clin Neurosci. 
2015;3:68–73.
•• An excellent paper about the different pharmacokinetic pro-
files of LD after LD/CD and LD/B administration in healthy 
subjects.
17. Heikkinen H, Varhe A, Laine T, et al. Entacapone improves the 
availability of L-dopa in plasma by decreasing its peripheral meta-
bolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol. 
2002;54:363–371.
•• The purpose of this study was to evaluate the effect of ENT 
(200 mg) in addition to standard LD/CD. They found that ENT 
increased AUC and decreased 3-OMD formation compared to 
PLC.
18. Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa 
exposure and reduces plasma levodopa variability when used with 
Sinemet CR. Clin Neuropharmacol. 2005;28:115–119.
•• To evaluate the effect of ENT (200 mg) in addition to CR LD/ 
CD. AUC increased, the 3-OMD level and daily LD plasma level 
decreased after ENT administration.
19. Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharma-
cokinetic profile of levodopa throughout the day between levo-
dopa/carbidopa/entacapone and levodopa/carbidopa when 
administered four or five times daily. Eur J Clin Pharmacol. 
2009;65:443–455.
•• The purpose of this study was to compare plasma LD concen-
trations after repeated LD/CD and LD/CD/ENT doses.
20. Müller T, Erdmann C, Muhlack S, et al. Pharmacokinetic ehavior of 
levodopa and 3-O-methyldopa after repeat administration of levo-
dopa/carbidopa with and without entacapone in patients with 
Parkinson’s disease. J Neural Transm (Vienna). 2006;113:1441–1448.
21. Müller T, Erdmann C, Muhlack S, et al. Inhibition of 
catechol-O-methyltransferase contributes to more stable levodopa 
plasma levels. Mov Disord. 2006;21:332–336.
22. Müller T, Ander L, Kolf K, et al. Comparison of 200 mg retarded 
release levodopa/carbidopa - with 150 mg levodopa/carbidopa/ 
entacapone application: pharmacokinetics and efficacy in patients 
with Parkinson’s disease. J Neural Transm (Vienna). 
2007;114:1457–1462.
•• Clinical and pharmacokinetic change assessment after ENT 
addition to RR LD/CD. In the LD/CD/ENT group members per-
formed significantly better in the attention-related tasks.
23. Müller T, Erdmann C, Muhlack S, et al. Entacapone improves com-
plex movement performance in patients with Parkinson’s disease. 
J Clin Neurosci. 2007;14:424–428.
24. Stocchi F, Barbato L, Nordera G, et al. Entacapone improves the 
pharmacokinetic and therapeutic response of controlled release 
levodopa/carbidopa in Parkinson’s patients. J Neural Transm 
(Vienna). 2004;111:173–180.
25. Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of 
levodopa/carbidopa/entacapone versus levodopa/carbidopa in 
early Parkinson’s disease. Mov Disord. 2009;24:541–550.
• A well-written paper, which concluded that over 39 weeks, in 
early PD patients, the LD/CD/ENT combination could result in 
a greater clinical improvement, without the augmentation of 
motor complication development.
26. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa 
therapy with and without entacapone in early Parkinson disease: 
the STRIDE-PD study. Ann Neurol. 2010;68:18–27.
•• This trial tested the hypothesis that ENT addition could reduce 
the risk of developing motor complications. Contrarily, they 
found that the LD/CD/ENT combination resulted in a shorter 
time to the onset of dyskinesia and increased the frequency.
27. Lyons KE, Pahwa R. Conversion from sustained release carbidopa/ 
levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson 
disease patients. Clin Neuropharmacol. 2006;29:73–76.
EXPERT OPINION ON PHARMACOTHERAPY 13
•• Conversion from SR LD/CD to LD/CD/ENT. For the majority of 
patients, quality of life and motor performance improved after 
shifting.
28. Myllylä V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with 
switching to Stalevo: an open-label evaluation in PD patients 
experiencing wearing-off (Simcom Study). Acta Neurol Scand. 
2006;114:181–186.
• The purpose of this study was to start LD/CD/ENT in patients 
who were previously treated with IR LD/DDCI plus separately 
administered ENT. 69% of the patients preferred (54%, N.S.) 
LD/CD/ENT or considered it as equivalent (15%) to previously 
applied treatment (N.S.).
29. Boiko AN, Batysheva TT, Minaeva NG, et al. Use of the new levo-
dopa agent Stalevo (levodopa/carbidopa/entacapone) in the treat-
ment of Parkinson’s disease in out-patient clinical practice (the 
START-M open trial). Neurosci Behav Physiol. 2008;38:933–936.
30. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled 
study of entacapone in levodopa-treated patients with stable Parkinson 
disease. Arch Neurol. 2004;61:1563–1568.
•• The clinical effect of ENT addition to LD in PD patients without 
motor complications was tested. They found that ENT addition 
significantly improved the QoL measures, however, the UPDRS 
score remained relatively unchanged.
31. Fung VS, Herawati L, Wan Y, et al. Quality of life in early Parkinson’s 
disease treated with levodopa/carbidopa/entacapone. Mov Disord. 
2009;24:25–31.
•• Comparison of LD/DDCI with LD/CD/ENT on quality of life in PD 
patients. There was a significant improvement in the PDQ-8 sum 
score and in a non-motor domain in the LD/CD/ENT group.
32. Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wear-
ing-off in parkinson’s disease: stalevo (levodopa/carbidopa/entaca-
pone) and levodopa/DDCI given in combination with Comtess/ 
Comtan (entacapone) provide equivalent improvements in symp-
tom control superior to that of traditional levodopa/DDCI treat-
ment. Eur Neurol. 2005;53:197–202.
• Switching from IR LD/DDCI to LD/DDCI + ENT (separately) or to 
LD/CD/ENT. There was no significant difference between the 
groups in the motor performance. However, the majority of 
patients preferred the LD/CD/ENT single tablet form.
33. Koller W, Guarnieri M, Hubble J, et al. An open-label evaluation of 
the tolerability and safety of Stalevo (carbidopa, levodopa and 
entacapone) in Parkinson’s disease patients experiencing wearing- 
off. J Neural Transm (Vienna). 2005;112:221–230.
34. Eggert K, Skogar O, Amar K, et al. Direct switch from levodopa/ 
benserazide or levodopa/carbidopa to levodopa/carbidopa/entaca-
pone in Parkinson’s disease patients with wearing-off: efficacy, 
safety and feasibility–an open-label, 6-week study. J Neural 
Transm (Vienna). 2010;117:333–342.
35. Lew MF, Somogyi M, McCague K, et al. Immediate versus delayed 
switch from levodopa/carbidopa to levodopa/carbidopa/entaca-
pone: effects on motor function and quality of life in patients 
with Parkinson’s disease with end-of-dose wearing off. 
Int J Neurosci. 2011;121:605–613.
•• The purpose of this study was to compare the effect of an immedi-
ate versus delayed switch from LD/CD to LD/CD/ENT on motor 
function and QoL. The immediate switch resulted in an earlier 
decrease in the UPDRS score and led to better QoL scores.
36. Delea TE, Thomas SK, Hagiwara M, et al. Adherence with levodopa/ 
carbidopa/entacapone versus levodopa/carbidopa and entacapone 
as separate tablets in patients with Parkinson’s disease. Curr Med 
Res Opin. 2010;26:1543–1552.
• Retrospective, observational cohort study which collected data 
on the adherence of PD patients receiving LD/CD/ENT or two 
separate tablets (LD/CD + ENT). The single tablet form led to 
better therapeutic adherence.
37. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in 
Parkinson’s disease. Mov Disord. 2009;24:2175–2186.
38. Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: defini-
tions, guidelines, and research perspectives in diagnosis. Ann 
Neurol. 2008;64:(S.2):81–92.
•• A great article which focuses on the important aspects of 
dementia related to Parkinson’s disease.
39. Insel K, Morrow D, Brewer B, et al. Executive function, working 
memory, and medication adherence among older adults. 
J Gerontol B Psychol Sci Soc Sci. 2006;61:102–107.
40. Stoehr GP, Lu SY, Lavery L, et al. Factors associated with adherence 
to medication regimens in older primary care patients: the Steel 
Valley Seniors Survey. Am J Geriatr Pharmacother. 2008;6:255–263.
41. Piccini P, Brooks DJ, Korpela K, et al. The catechol- 
O-methyltransferase (COMT) inhibitor entacapone enhances the 
pharmacokinetic and clinical response to Sinemet CR in 
Parkinson’s disease. J Neurol Neurosurg Psychiatry. 
2000;68:589–594.
•• The purpose of this study was to test the clinical consequence 
of ENT addition to standard LD versus CR LD. UPDRS improve-
ment was higher in the CR LD/CD + ENT group compared to CR 
LD/CD + PLC group.
42. Müller T, Kolf K, Ander L, et al. Catechol-O-methyltransferase inhibi-
tion improves levodopa-associated strength increase in patients 
with Parkinson disease. Clin Neuropharmacol. 2008;31:134–140.
43. Tolosa E, Hernández B, Linazasoro G, et al. Efficacy of levodopa/ 
carbidopa/entacapone versus levodopa/carbidopa in patients with 
early Parkinson’s disease experiencing mild wearing-off: 
a randomised, double-blind trial. J Neural Transm (Vienna). 
2014;121:357–366.
•• LD/CD/ENT versus LD/CD in early PD patients experiencing 
mild or only minimally disabling wearing-off. Treatment with 
LD/CD/ENT resulted in significant improvement in the UPDRS 
scale part II.
44. Hsu A, Yao HM, Gupta S, et al. Comparison of the pharmacokinetics 
of an oral extended-release capsule formulation of carbidopa- 
levodopa (IPX066) with immediate-release carbidopa-levodopa 
(Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) 
CR), and carbidopa-levodopa-entacapone (Stalevo(®)). J Clin 
Pharmacol. 2015;55:995–1003.
45. Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus 
among movement disorder specialists on clinical indicators for 
identification and management of advanced Parkinson’s disease: 
a multi-country Delphi-panel approach. Curr Med Res Opin. 
2018;34:2063–2073.
•• An excellent consensus paper, which emphasizes the impor-
tance of early recognition of patients with advanced stage 
disease to improve the QoL by applying device-aided 
therapies.
14 A. SALAMON ET AL.
